Adenosine receptors and caffeine in retinopathy of prematurity

Jiang Fan Chen, Shuya Zhang, Rong Zhou, Zhenlang Lin, Xiaohong Cai, Jing Lin, Yuqing Huo, Xiaoling Liu

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy.

Original languageEnglish (US)
Pages (from-to)118-125
Number of pages8
JournalMolecular Aspects of Medicine
Volume55
DOIs
StatePublished - Jun 1 2017

Fingerprint

Retinopathy of Prematurity
Purinergic P1 Receptors
Caffeine
Oxygen
Pathologic Neovascularization
Adenosine
Vascular Endothelial Growth Factor A
Purinergic P1 Receptor Antagonists
Therapeutics
Hyperoxia
Animals
Therapeutic Uses
Blindness
Premature Infants
Blood Vessels
Retina
Clinical Trials
Growth

Keywords

  • Adenosine
  • Adenosine (A, A, A) receptors
  • Caffeine
  • Oxygen-induced retinopathy
  • Retinopathy of prematurity

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Chen, J. F., Zhang, S., Zhou, R., Lin, Z., Cai, X., Lin, J., ... Liu, X. (2017). Adenosine receptors and caffeine in retinopathy of prematurity. Molecular Aspects of Medicine, 55, 118-125. https://doi.org/10.1016/j.mam.2017.01.001

Adenosine receptors and caffeine in retinopathy of prematurity. / Chen, Jiang Fan; Zhang, Shuya; Zhou, Rong; Lin, Zhenlang; Cai, Xiaohong; Lin, Jing; Huo, Yuqing; Liu, Xiaoling.

In: Molecular Aspects of Medicine, Vol. 55, 01.06.2017, p. 118-125.

Research output: Contribution to journalReview article

Chen, JF, Zhang, S, Zhou, R, Lin, Z, Cai, X, Lin, J, Huo, Y & Liu, X 2017, 'Adenosine receptors and caffeine in retinopathy of prematurity', Molecular Aspects of Medicine, vol. 55, pp. 118-125. https://doi.org/10.1016/j.mam.2017.01.001
Chen, Jiang Fan ; Zhang, Shuya ; Zhou, Rong ; Lin, Zhenlang ; Cai, Xiaohong ; Lin, Jing ; Huo, Yuqing ; Liu, Xiaoling. / Adenosine receptors and caffeine in retinopathy of prematurity. In: Molecular Aspects of Medicine. 2017 ; Vol. 55. pp. 118-125.
@article{62ffdacdd36644b897948c884dafce20,
title = "Adenosine receptors and caffeine in retinopathy of prematurity",
abstract = "Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy.",
keywords = "Adenosine, Adenosine (A, A, A) receptors, Caffeine, Oxygen-induced retinopathy, Retinopathy of prematurity",
author = "Chen, {Jiang Fan} and Shuya Zhang and Rong Zhou and Zhenlang Lin and Xiaohong Cai and Jing Lin and Yuqing Huo and Xiaoling Liu",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.mam.2017.01.001",
language = "English (US)",
volume = "55",
pages = "118--125",
journal = "Molecular Aspects of Medicine",
issn = "0098-2997",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Adenosine receptors and caffeine in retinopathy of prematurity

AU - Chen, Jiang Fan

AU - Zhang, Shuya

AU - Zhou, Rong

AU - Lin, Zhenlang

AU - Cai, Xiaohong

AU - Lin, Jing

AU - Huo, Yuqing

AU - Liu, Xiaoling

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy.

AB - Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy.

KW - Adenosine

KW - Adenosine (A, A, A) receptors

KW - Caffeine

KW - Oxygen-induced retinopathy

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=85010943948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010943948&partnerID=8YFLogxK

U2 - 10.1016/j.mam.2017.01.001

DO - 10.1016/j.mam.2017.01.001

M3 - Review article

VL - 55

SP - 118

EP - 125

JO - Molecular Aspects of Medicine

JF - Molecular Aspects of Medicine

SN - 0098-2997

ER -